Bill & Melinda Gates Foundation - Pharmaceuticals & Healthcare - Deals and Alliances Profile
September 2018
74
About the Report
About the Report
Summary
Bill & Melinda Gates Foundation (BMGF), formerly William H. Gates Foundation is a provider of health development programs. The foundation concentrates on improving healthcare, decrease poverty in America and provides access to information equipment. It offers global health services in the fields of discovery and translational sciences, enteric and diarrheal diseases, HIV, malaria, neglected infectious diseases, and tuberculosis services. BMGF's global development services include agricultural development, family planning, emergency response, financial services for the poor, nutrition fulfillment, vaccine delivery, and water, sanitation and hygiene services. The foundation has its presence in Asia, Africa, Europe, North America, South America, and Oceania. BMGF is headquartered in Seattle, Washington, the US.
Bill & Melinda Gates Foundation-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Bill & Melinda Gates Foundation, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Bill & Melinda Gates Foundation, Medical Devices Deals, 2012 to YTD 2018 10
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deal Details 15
Venture Financing 15
Evolve BioSystems Raises USD40 Million in Series C Financing 15
Visterra Raises Additional USD23.6 Million in Series C Financing 17
Arsanis Raises USD45.5 Million in Series D Financing 19
Vir Biotech Raises Funds through Venture Financing 21
Kymab Raises USD100.5 Million in Series C Financing 22
Just Biotherapeutics Raises USD14 Million in Series A2 Financing 24
Affinivax Raises USD2.5 Million in Venture Financing 26
Lodo Therapeutics Raises USD17 Million in Series A Financing 27
Atreca Raises USD56 Million in Series A Financing 29
CureVac to Raise USD76 Million in Venture Financing 30
Affinivax Raises USD4 Million in Seed Venture Financing 31
Synlogic Raises Additional USD5 Million in Series A Venture Financing 32
Kymab Raises USD40 Million in Series B Financing 33
Visterra Raises USD 8.1 Million In Extended Series A Financing 34
Visterra Raises Additional USD 13 Million In Series A Financing 36
Genocea Biosciences Raises USD 30 Million In Series C Financing 38
Partnerships 40
Novartis and Bill & Melinda Gates Foundation Enter into Partnership 40
CureVac to Enter into Development Agreement with Bill & Melinda Gates 41
Sanofi Pasteur Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 42
GSK Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 43
Anacor Pharma Amends Research Agreement With Bill & Melinda Gates Foundation 44
Atreca Enters into Agreement with Bill & Melinda Gates Foundation 45
Equity Offering 46
Achaogen to Raise USD10 Million in Private Placement of Shares 46
Intarcia Therapeutics Raises USD206 Million in Second Tranche of Private Placement of Shares 47
CureVac Raises USD110 Million in Private Placement of Shares 48
Bill & Melinda Gates Foundation-Key Competitors 49
Bill & Melinda Gates Foundation-Key Employees 50
Bill & Melinda Gates Foundation-Locations And Subsidiaries 51
Head Office 51
Other Locations & Subsidiaries 51
Joint Venture 51
Recent Developments 53
Government and Public Interest 53
Aug 03, 2018: HitGen launching initiative to discover new medicines to combat tuberculosis and malaria 53
Jun 28, 2018: SwRI receives grant to reduce the cost of current malaria treatment 54
Jun 06, 2018: Latest Gates Foundation grants will advance research on educational inclusion and global immunization 55
May 16, 2018: Molecular Health to pursue drug repurposing in tuberculosis treatment and perinatal complications 56
May 15, 2018: Aiming Low: Landmark study optimises steroid use in pregnancy 57
Apr 27, 2018: Sabin Vaccine Institute Issues Statement on New Universal Flu Vaccine Development Grand Challenge 58
Feb 13, 2018: CureVac to Pursue Innovative mRNA Vaccines Against Flu and Malaria 59
Feb 12, 2018: Inovio and The Wistar Institute Receive More Than USD 4.6 Million in R&D Funding to Advance Vaccines Against Tuberculosis & Malaria 60
Dec 13, 2017: Sirenas Receives Research Grant Totaling USD 1.68 M To Accelerate Its Drug Discovery Technology, ATLANTIS 61
Nov 29, 2017: Phyton Biotech Wins Grant to Develop New Approaches to Manufacturing Artemisinin 62
Nov 09, 2017: PeptiDream Receives Grant to Discover and Develop Novel Therapeutics for Infectious Disease 63
Oct 23, 2017: Ventria Bioscience aids global fight against intestinal infections that threaten up to 400 million children a year 64
Sep 08, 2017: Malaria: Drug Candidate May Reduce Spread of the Parasite 65
Aug 18, 2017: IHI Partners with South Africa National Department of Health on Initiative to Improve Tuberculosis Care and Outcomes 67
Jun 12, 2017: Rotary and the Bill & Melinda Gates Foundation announce USD 450 million commitment to end polio 68
Mar 06, 2017: Vaxess Technologies Receives Grants Totaling USD 6 Million to Develop Microneedle Vaccines for Polio, Measles, Rubella 69
Jan 09, 2017: Kymab expands Infectious Disease Programmes 70
Other Significant Developments 71
Mar 28, 2018: As the GHIT Fund Closes Out First Five Years of R&D for Lifesaving Medical Breakthroughs, It Launches Next Phase, Focusing on Access and Delivery, Bringing Total Investment to 13.2 Billion Yen (USD 123 Million) 71
Appendix 74
Methodology 74
About GlobalData 74
Contact Us 74
Disclaimer 74
List of Figure
List of Figures
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Bill & Melinda Gates Foundation, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Key Facts 2
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bill & Melinda Gates Foundation, Deals By Therapy Area, 2012 to YTD 2018 9
Bill & Melinda Gates Foundation, Medical Devices Deals, 2012 to YTD 2018 10
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Evolve BioSystems Raises USD40 Million in Series C Financing 15
Visterra Raises Additional USD23.6 Million in Series C Financing 17
Arsanis Raises USD45.5 Million in Series D Financing 19
Vir Biotech Raises Funds through Venture Financing 21
Kymab Raises USD100.5 Million in Series C Financing 22
Just Biotherapeutics Raises USD14 Million in Series A2 Financing 24
Affinivax Raises USD2.5 Million in Venture Financing 26
Lodo Therapeutics Raises USD17 Million in Series A Financing 27
Atreca Raises USD56 Million in Series A Financing 29
CureVac to Raise USD76 Million in Venture Financing 30
Affinivax Raises USD4 Million in Seed Venture Financing 31
Synlogic Raises Additional USD5 Million in Series A Venture Financing 32
Kymab Raises USD40 Million in Series B Financing 33
Visterra Raises USD 8.1 Million In Extended Series A Financing 34
Visterra Raises Additional USD 13 Million In Series A Financing 36
Genocea Biosciences Raises USD 30 Million In Series C Financing 38
Novartis and Bill & Melinda Gates Foundation Enter into Partnership 40
CureVac to Enter into Development Agreement with Bill & Melinda Gates 41
Sanofi Pasteur Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 42
GSK Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 43
Anacor Pharma Amends Research Agreement With Bill & Melinda Gates Foundation 44
Atreca Enters into Agreement with Bill & Melinda Gates Foundation 45
Achaogen to Raise USD10 Million in Private Placement of Shares 46
Intarcia Therapeutics Raises USD206 Million in Second Tranche of Private Placement of Shares 47
CureVac Raises USD110 Million in Private Placement of Shares 48
Bill & Melinda Gates Foundation, Key Competitors 49
Bill & Melinda Gates Foundation, Key Employees 50
Bill & Melinda Gates Foundation, Other Locations 51
Bill & Melinda Gates Foundation, Subsidiaries 51
Bill & Melinda Gates Foundation, Joint Venture 51
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.